Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Omeros Corp Is An Inventive, Commercial-Stage Biotechnology Company That Discovers And Develops First-In-Class Protein And Small-Molecule Therapeutics For Large-Market And Orphan Indications, With Particular Emphasis On Complement-Mediated Diseases, Cancers, And Addictive Or Compulsive Disorders. The Company'S Clinical-Stage Development Programs Include: Narsoplimab, Its Antibody Targeting Mannan-Binding Lectin-Associated Serine Protease 2 (Masp-2), The Effector Enzyme Of The Lectin Pathway Of Complement; Oms1029, Its Long-Acting Antibody Targeting Masp-2; And Oms527, Its Phosphodiesterase 7 (Pde7) Inhibitor Program.